Form 4 for RVMD Revolution Medicines, Inc.
Accepted 2026-09-24 18:00:04 ET · period of report 2026-09-22 · accession 0001758247-26-000004 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DT | 2026-09-24 18:00 | 2026-09-22 | RVMD | ANDERSON ELIZABETH M | Dir | M - OptEx | $1.12 | +5,070 | 14.5K | +54% | +$5,678 |
| DMT | 2026-09-24 18:00 | 2026-09-22 | RVMD | ANDERSON ELIZABETH M | Dir | S - Sale+OE | $193.04 | -10.1K | 4,333 | -70% | -$1.96M |
| DT | 2026-09-24 18:00 | 2026-09-22 | RVMD | ANDERSON ELIZABETH M | Dir | M - OptEx | $0.00 | -5,070 | 1,095 | -82% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-09-22 | M | A | 5,070 | $1.12 | 14,476 | D | — | — | (F1) Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on June 23, 2026. |
| 2 | Common | Common Stock | 2026-09-22 | S | D | 910 | $191.85 | 13,566 | D | — | — | (F1) Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on June 23, 2026. (F2) The transaction was executed in multiple trades at prices ranging from $191.65 to $191.99, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. |
| 3 | Common | Common Stock | 2026-09-22 | S | D | 4,985 | $192.54 | 8,581 | D | — | — | (F1) Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on June 23, 2026. (F3) The transaction was executed in multiple trades at prices ranging from $192.01 to $192.99, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. |
| 4 | Common | Common Stock | 2026-09-22 | S | D | 2,648 | $193.44 | 5,933 | D | — | — | (F1) Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on June 23, 2026. (F4) The transaction was executed in multiple trades at prices ranging from $193.00 to $193.81, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. |
| 5 | Common | Common Stock | 2026-09-22 | S | D | 1,500 | $194.59 | 4,433 | D | — | — | (F1) Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on June 23, 2026. (F5) The transaction was executed in multiple trades at prices ranging from $194.04 to $194.96, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. |
| 6 | Common | Common Stock | 2026-09-22 | S | D | 100 | $195.15 | 4,333 | D | — | — | (F1) Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on June 23, 2026. (F6) Includes 1,191 restricted stock units. |
| 7 | Derivative | Stock Option (Right to Buy) | 2026-09-22 | M | D | 5,070 | $0.00 | 1,095 | D | $1.12 · — to 2028-04-19 | 6,165 Common Stock | (F1) Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on June 23, 2026. (F9) Fully vested. |